Form 4: Fate Therapeutics Director Michael Lee Awarded Stock Options

Michael Lee, a director of Fate Therapeutics, was granted stock options for 40,000 shares in connection with his board service.

Summary

• Michael Lee, a director of Fate Therapeutics, was granted a stock option to purchase 40,000 shares of common stock.
• The options were granted on June 7, 2024, with an exercise price of $3.68 per share.
• The stock option will vest in full and become exercisable upon the earlier of June 7, 2025, or the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to Michael Lee's continued service on the board of directors of the Issuer through the applicable vesting date.
• Lee is a managing director of Redmile Group, LLC, and was elected to the board as a representative of Redmile and its affiliates.
• Lee holds the stock option award as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option award to Redmile.
• Lee disclaims beneficial ownership of the stock option award.
• Jeremy Green, as the principal of Redmile, may also be deemed to beneficially own the stock option award.
• Redmile and Mr. Green disclaim beneficial ownership of the stock option award except to the extent of their pecuniary interest therein.

Sentiment

Score: 6

Explanation: The document is a routine filing related to stock option grants, which is generally neutral. The fact that a director is receiving options is a slightly positive sign, indicating continued involvement and alignment with company goals.

Positives

• Granting stock options to directors can align their interests with those of the shareholders.

Future Outlook

The stock options vest based on continued service, suggesting an expectation of ongoing board involvement from Michael Lee.

Industry Context

Stock option grants are a common form of compensation for directors, particularly in the biotechnology industry, to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants to board members are a common practice across the biotechnology industry.
• The size of the grant (40,000 shares) and the vesting schedule (one year) appear to be within typical ranges for director compensation at comparable companies.
• Companies like Juno Therapeutics (acquired by Celgene) and Kite Pharma (acquired by Gilead) also used stock options as part of their director compensation packages.

Related Party Transactions

• Michael Lee, as a managing director of Redmile Group, LLC, was elected to the board of the Issuer as a representative of Redmile and its affiliates.
• Mr. Lee holds this stock option award as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option award to Redmile.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.
• The grant incentivizes the director to act in the best interests of the company, which could benefit all stakeholders.

Key Dates